Уровень 0 · материалов: 3
В кластер включены документы о передовых методах таргетного воздействия на раковые клетки с использованием иммунных механизмов или пептидов, и исключены любые методы общего лечения без персонализации.
Общие признаки: инновационное лечение рака, модификация иммунной системы, преодоление резистентности опухолей, индивидуальный подход к терапии
Группа выше: Онкология
Смысл: The text describes a successful medical case where a woman with terminal metastatic breast cancer achieved full remission through the use of expanded tumor-infiltrating lymphocytes (TIL). It explains the scientific process of TIL therapy and its potential application to other epithelial cancers, while cautiously noting the challenges of treatment resistance and scalability.
A woman with terminal metastatic breast cancer achieved full remission through a personalized immunotherapy that expands her own tumor-infiltrating lymphocytes to fight the disease.
Смысл: The main idea is the transformative potential and inherent risks of CAR-T cell therapy, illustrated through the pioneering case of William Ludwig. It demonstrates how genetic engineering can 'reprogram' the immune system to destroy previously untreatable cancers, while cautioning that the technology still faces significant safety and precision hurdles.
The story of William Ludwig, the first human to be cured of multiple cancers using genetically engineered CAR-T cells, highlighting the breakthrough and risks of immunotherapy.
Смысл: The main idea is that AEBi has developed a multi-target peptide-based therapy (MuTaTo) designed to overcome cancer's ability to mutate and resist treatment, potentially providing a fast, low-cost, and universal personalized cure.
Israeli company AEBi has developed MuTaTo, a personalized multi-target peptide therapy designed to kill cancer cells and stem cells while preventing resistance through mutation.